Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma

Tatsuro Okamoto, Hirokazu Kitahara, Shinichiro Shimamatsu, Masakazu Katsura, Kazuki Takada, Takatoshi Fujishita, Yuzo Suzuki, Yosuke Morodomi, Tetsuzo Tagawa, Yoshihiko Maehara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: The purpose of this study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) sensitizing mutations in patients with lung adenocarcinoma who underwent complete surgical resection. Patients and Methods: We retrospectively reviewed the clinical records of 164 patients with lung adenocarcinoma who underwent surgery from 2003 to 2010. Seventy-four patients harbored EGFR mutations; two with exon 18 mutations, 27 with exon 19 mutations, and 45 with exon 21 mutations. Results: There were more female patients and more never-/light smokers among patients with EGFR mutations than among patients without EGFR mutations. Patients with EGFR mutations had a trend for better disease-free survival and overall survival compared to patients without EGFR mutations (p=0.068 and p=0.049, respectively). Patients with exon 21 mutations had significantly better disease-free survival than patients with exon 19 mutations (p=0.027). Conclusion: Adenocarcinomas harboring EGFR exon 21 mutation were less malignant than adenocarcinomas harboring exon 19 mutation.

Original languageEnglish
Pages (from-to)3057-3063
Number of pages7
JournalAnticancer research
Volume36
Issue number6
Publication statusPublished - Jun 2016

Fingerprint

Epidermal Growth Factor Receptor
Recurrence
Mutation
Exons
Adenocarcinoma of lung
Disease-Free Survival
Adenocarcinoma

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Okamoto, T., Kitahara, H., Shimamatsu, S., Katsura, M., Takada, K., Fujishita, T., ... Maehara, Y. (2016). Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma. Anticancer research, 36(6), 3057-3063.

Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma. / Okamoto, Tatsuro; Kitahara, Hirokazu; Shimamatsu, Shinichiro; Katsura, Masakazu; Takada, Kazuki; Fujishita, Takatoshi; Suzuki, Yuzo; Morodomi, Yosuke; Tagawa, Tetsuzo; Maehara, Yoshihiko.

In: Anticancer research, Vol. 36, No. 6, 06.2016, p. 3057-3063.

Research output: Contribution to journalArticle

Okamoto, T, Kitahara, H, Shimamatsu, S, Katsura, M, Takada, K, Fujishita, T, Suzuki, Y, Morodomi, Y, Tagawa, T & Maehara, Y 2016, 'Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma', Anticancer research, vol. 36, no. 6, pp. 3057-3063.
Okamoto T, Kitahara H, Shimamatsu S, Katsura M, Takada K, Fujishita T et al. Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma. Anticancer research. 2016 Jun;36(6):3057-3063.
Okamoto, Tatsuro ; Kitahara, Hirokazu ; Shimamatsu, Shinichiro ; Katsura, Masakazu ; Takada, Kazuki ; Fujishita, Takatoshi ; Suzuki, Yuzo ; Morodomi, Yosuke ; Tagawa, Tetsuzo ; Maehara, Yoshihiko. / Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma. In: Anticancer research. 2016 ; Vol. 36, No. 6. pp. 3057-3063.
@article{a84291b463ab4fa9a287db4e167e7bc2,
title = "Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma",
abstract = "Aim: The purpose of this study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) sensitizing mutations in patients with lung adenocarcinoma who underwent complete surgical resection. Patients and Methods: We retrospectively reviewed the clinical records of 164 patients with lung adenocarcinoma who underwent surgery from 2003 to 2010. Seventy-four patients harbored EGFR mutations; two with exon 18 mutations, 27 with exon 19 mutations, and 45 with exon 21 mutations. Results: There were more female patients and more never-/light smokers among patients with EGFR mutations than among patients without EGFR mutations. Patients with EGFR mutations had a trend for better disease-free survival and overall survival compared to patients without EGFR mutations (p=0.068 and p=0.049, respectively). Patients with exon 21 mutations had significantly better disease-free survival than patients with exon 19 mutations (p=0.027). Conclusion: Adenocarcinomas harboring EGFR exon 21 mutation were less malignant than adenocarcinomas harboring exon 19 mutation.",
author = "Tatsuro Okamoto and Hirokazu Kitahara and Shinichiro Shimamatsu and Masakazu Katsura and Kazuki Takada and Takatoshi Fujishita and Yuzo Suzuki and Yosuke Morodomi and Tetsuzo Tagawa and Yoshihiko Maehara",
year = "2016",
month = "6",
language = "English",
volume = "36",
pages = "3057--3063",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Prognostic impact of EGFR driver mutations on postoperative disease recurrence in lung adenocarcinoma

AU - Okamoto, Tatsuro

AU - Kitahara, Hirokazu

AU - Shimamatsu, Shinichiro

AU - Katsura, Masakazu

AU - Takada, Kazuki

AU - Fujishita, Takatoshi

AU - Suzuki, Yuzo

AU - Morodomi, Yosuke

AU - Tagawa, Tetsuzo

AU - Maehara, Yoshihiko

PY - 2016/6

Y1 - 2016/6

N2 - Aim: The purpose of this study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) sensitizing mutations in patients with lung adenocarcinoma who underwent complete surgical resection. Patients and Methods: We retrospectively reviewed the clinical records of 164 patients with lung adenocarcinoma who underwent surgery from 2003 to 2010. Seventy-four patients harbored EGFR mutations; two with exon 18 mutations, 27 with exon 19 mutations, and 45 with exon 21 mutations. Results: There were more female patients and more never-/light smokers among patients with EGFR mutations than among patients without EGFR mutations. Patients with EGFR mutations had a trend for better disease-free survival and overall survival compared to patients without EGFR mutations (p=0.068 and p=0.049, respectively). Patients with exon 21 mutations had significantly better disease-free survival than patients with exon 19 mutations (p=0.027). Conclusion: Adenocarcinomas harboring EGFR exon 21 mutation were less malignant than adenocarcinomas harboring exon 19 mutation.

AB - Aim: The purpose of this study was to investigate the prognostic significance of epidermal growth factor receptor (EGFR) sensitizing mutations in patients with lung adenocarcinoma who underwent complete surgical resection. Patients and Methods: We retrospectively reviewed the clinical records of 164 patients with lung adenocarcinoma who underwent surgery from 2003 to 2010. Seventy-four patients harbored EGFR mutations; two with exon 18 mutations, 27 with exon 19 mutations, and 45 with exon 21 mutations. Results: There were more female patients and more never-/light smokers among patients with EGFR mutations than among patients without EGFR mutations. Patients with EGFR mutations had a trend for better disease-free survival and overall survival compared to patients without EGFR mutations (p=0.068 and p=0.049, respectively). Patients with exon 21 mutations had significantly better disease-free survival than patients with exon 19 mutations (p=0.027). Conclusion: Adenocarcinomas harboring EGFR exon 21 mutation were less malignant than adenocarcinomas harboring exon 19 mutation.

UR - http://www.scopus.com/inward/record.url?scp=84991711478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991711478&partnerID=8YFLogxK

M3 - Article

C2 - 27272827

AN - SCOPUS:84991711478

VL - 36

SP - 3057

EP - 3063

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -